PainReform Stock (NASDAQ:PRFX)

Ownership Financials Chart

Previous Close

$11.16

52W Range

$0.43 - $20.16

50D Avg

$1.74

200D Avg

$3.61

Market Cap

$608.66K

Avg Vol (3M)

$5.61M

Beta

0.56

Div Yield

PRFX Company Profile

PainReform Ltd., a clinical stage specialty pharmaceutical company, engages in the development of therapeutics that provides an extended period of post-surgical pain relief in Israel. It engages in developing PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia. The company is currently conducting two Phase 3 clinical trials of PRF-110 for the treatment of patients undergoing bunionectomy surgery and hernia repair. PainReform Ltd. was incorporated in 2007 and is based in Tel Aviv, Israel.

Industry

Drug Manufacturers - Specialty & Generic

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

IPO Date

Sep 01, 2020

Website

PRFX Performance

PRFX Financial Summary

	Dec 23	Dec 22	Dec 21
Revenue	-	$86.00K	-
Operating Income	$-9.58M	$-8.87M	$-7.21M
Net Income	$-9.34M	$-8.79M	$-7.25M
EBITDA	$-9.57M	$-8.71M	$-7.21M
Basic EPS	$-7.14	$-8.25	$-7.38
Diluted EPS	$-7.14	$-8.25	$-7.38

Fiscal year ends in Dec 23 | Currency in USD

Peer Comparison

Ticker	Company
INCR	InterCure Ltd.
FLGC	Flora Growth Corp.
RGC	Regencell Bioscience Holdings Limited
PROC	Procaps Group S.A.